As we previously reported31 in prostate tumors CXCL12–CXCR4 signaling activates STAT3, NFκB, and AKT pathways, which are the likely mechanistic culprits of CXCL12 effects on cancer aggressiveness. This evidence concerns the gene STAT3 and prostate neoplasm.